MergerMay 7, 2026, 05:27 PM
Shuttle Pharma Completes Merger with United Dogecoin
AI Summary
Shuttle Pharmaceuticals Holdings, Inc. completed its previously announced merger with United Dogecoin Inc. on May 6, 2026, making United Dogecoin Inc. a direct wholly-owned subsidiary. As consideration, existing United Dogecoin shareholders received 8,403 shares of newly designated Series B-1 convertible preferred stock, convertible into 4,033 shares of Shuttle common stock per share at $1.24, subject to approval. Additionally, up to 122,927,528 Pre-Funded Warrants are issuable upon milestone achievements. The company also closed a PIPE financing, issuing 1,910 shares of Series B-2 preferred stock and common stock purchase warrants exercisable at $1.03 per share.
Key Highlights
- Shuttle Pharmaceuticals completed its merger with United Dogecoin Inc. on May 6, 2026.
- United Dogecoin Inc. became a direct wholly-owned subsidiary of Shuttle Pharmaceuticals.
- 8,403 shares of Series B-1 convertible preferred stock were issued as merger consideration.
- Each Series B-1 Preferred Stock is convertible into 4,033 shares of common stock at $1.24, subject to stockholder approval.
- Up to 122,927,528 Pre-Funded Warrants are issuable upon milestone events, subject to stockholder approval.
- Financial advisor E.F. Hutton & Co. received 750 Series B-1 Preferred Stock shares and Pre-Funded Warrants.
- Shuttle Pharmaceuticals closed a PIPE financing, issuing 1,910 Series B-2 preferred stock and common warrants.
- Common Warrants from PIPE financing are exercisable at $1.03 per share for three years.
Price Impact
More from SHPH